Morgan Stanley Previews F1Q12 at Medtronic

Morgan Stanley has published a research report on Medtronic Inc MDT. In the report, Morgan Stanley wrote, "Consensus EPS of $0.79 (MS of $0.80) and revenue of $3.98bn (MS of $4.02mn) seem achievable. Our CRM numbers are likely adequately conservative but our Spine numbers, specifically InFuse, may be at risk, though risk to overall results is likely in the ~1% range." Morgan Stanley rated Medtronic an Equal-weight with no price target given. Medtronic closed Thursday at $31.25.